接受所有 Cookie 可以确保在我们网站上获得良好的用户体验,包括个性化的内容和社交媒体功能。仅接受必要的 Cookie 将在您浏览时使用最少的 Cookie,但是网站上的部分内容可能无法正确显示。如需了解更多信息,请查看我们的 隐私政策。
Alignment of Data Requirements by Regulators to Stimulate the Development of New Antibiotics
September 9, 2016
Alignment of data requirements by regulators worldwide can contribute to stimulate the development of new antibiotics to fight antimicrobial resistance and protect global public health. However, regulatory activities are only one element of the comprehensive and multifaceted response needed to encourage and accelerate development of new antibacterial medicines that meet patient needs.
This was one of the conclusions reached at a meeting between the European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the United States' Food and Drug Administration (FDA) hosted by EMA on 1-2 September 2016.
At their tripartite meeting, the three agencies also agreed that some flexibility should be applied to the requirements for clinical development programmes for antibacterial agents, in particular where treatment options for patients are limited due to antimicrobial resistance.
In addition, participants reiterated that it may be appropriate to accept abbreviated clinical development programmes for new antibiotics that can address an unmet need related to antimicrobial resistance.
With a view to better understand the similarities and differences between the clinical data requirements of the three regulatory systems, the participants discussed approaches to clinical trial design, including choice of endpoints, as well as post-authorisation monitoring activities for antibacterial medicines.
They also identified areas of closer collaboration and coordination of efforts to encourage the development of safe and effective antibacterial treatments.
Source: EMA